BerGenBio
Bergen
About BerGenBio
BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $183.4M
- Funding stage: IPO
- Last round: Post-IPO Debt (Nov 2023)
- Ticker: ose:BGBIO
- Website: bergenbio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/bergenbio-26397 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.